Advertisement
Advertisement
U.S. markets open in 18 minutes
S&P Futures
4,344.00 -17.00 (-0.39%) Dow Futures
34,127.00 -105.00 (-0.31%) Nasdaq Futures
14,808.75 -60.75 (-0.41%) Russell 2000 Futures
1,781.90 -10.80 (-0.60%) Crude Oil
90.08 +0.05 (+0.06%) Gold
1,945.30 -0.30 (-0.02%)
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
Pre-Market:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 173.85 |
| Open | 173.85 |
| Bid | 150.00 x 1400 |
| Ask | 171.95 x 900 |
| Day's Range | 169.85 - 174.51 |
| 52 Week Range | 169.85 - 242.97 |
| Volume | |
| Avg. Volume | 572,777 |
| Market Cap | 21.444B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.56 |
| Earnings Date | Oct 25, 2023 - Oct 30, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 247.55 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for ALNY
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Alnylam Pharmaceuticals, Inc.Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.RatingFair ValueEconomic Moat2 months agoMorningstar
Insider Monkey13 Best Beaten Down Stocks To Buy Now
In this article, we will be taking a look at the 13 best beaten down stocks to buy now. To skip our detailed analysis of the US stock market and recent developments within it, you can go directly to see the 5 Best Beaten Down Stocks To Buy Now. The Two-Day Fed Meeting On September […]
Investor's Business DailyAlnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.
ZacksAlnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod
Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
